Symbols / PSTV Stock $7.28 -4.46% Plus Therapeutics, Inc.
PSTV (Stock) Chart
About
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Stock Fundamentals
Scroll to Statements| Market Cap | 49.96M | Enterprise Value | 42.16M | Income | -22.39M | Sales | 5.21M | Book/sh | 0.72 | Cash/sh | 1.25 |
| Dividend Yield | — | Payout | 0.00% | Employees | 28 | IPO | — | P/E | — | Forward P/E | -3.09 |
| PEG | 2.45 | P/S | 9.58 | P/B | 10.11 | P/C | — | EV/EBITDA | -2.84 | EV/Sales | 8.09 |
| Quick Ratio | 0.73 | Current Ratio | 1.23 | Debt/Eq | 20.55 | LT Debt/Eq | — | EPS (ttm) | -7.25 | EPS next Y | -2.35 |
| EPS Growth | — | Revenue Growth | -3.20% | Earnings | 2026-03-04 | ROA | -83.29% | ROE | — | ROIC | — |
| Gross Margin | -60.73% | Oper. Margin | -4.20% | Profit Margin | 0.00% | Shs Outstand | 6.86M | Shs Float | 6.33M | Short Float | 14.01% |
| Short Ratio | 5.14 | Short Interest | — | 52W High | 23.50 | 52W Low | 2.90 | Beta | 1.02 | Avg Volume | 391.50K |
| Volume | 213.81K | Target Price | $38.00 | Recom | Buy | Prev Close | $7.62 | Price | $7.28 | Change | -4.46% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-09 | main | Ascendiant Capital | Buy → Buy | $65 |
| 2026-03-31 | down | D. Boral Capital | Buy → Hold | — |
| 2026-03-19 | main | D. Boral Capital | Buy → Buy | $3 |
| 2026-01-23 | main | HC Wainwright & Co. | Buy → Buy | $1 |
| 2026-01-22 | main | D. Boral Capital | Buy → Buy | $4 |
| 2026-01-08 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-12-11 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-12-01 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-11-21 | main | Ascendiant Capital | Buy → Buy | $19 |
| 2025-11-20 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-11-03 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-10-31 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-10-21 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-10-06 | main | Ascendiant Capital | Buy → Buy | $21 |
| 2025-09-25 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-09-22 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-09-18 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-09-03 | up | D. Boral Capital | Hold → Buy | $5 |
| 2025-08-18 | main | Maxim Group | Buy → Buy | $3 |
| 2025-06-27 | main | HC Wainwright & Co. | Buy → Buy | $3 |
- PSTV Stock On Track For Best Week Since September — Here’s What Is Driving The Rally - Stocktwits Fri, 10 Apr 2026 19
- Indiana facility becomes second production site for CNS cancer drug - Stock Titan hu, 23 Apr 2026 11
- PSTV Stock Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill Mon, 20 Apr 2026 07
- Plus Therapeutics regains compliance with Nasdaq - MSN hu, 23 Apr 2026 22
- Why Is Plus Therapeutics Stock Gaining Friday? - Plus Therapeutics (NASDAQ:PSTV) - Benzinga Fri, 10 Apr 2026 07
- $PSTV stock is down 13% today. Here's what we see in our data. - Quiver Quantitative ue, 07 Apr 2026 07
- Plus Therapeutics Announces Reverse Stock Split - Yahoo Finance ue, 31 Mar 2026 07
- New Plus Therapeutics development chief gets 20,000 options and RSUs - Stock Titan Wed, 22 Apr 2026 20
- Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4 - Yahoo Finance hu, 12 Mar 2026 07
- Plus Therapeutics clears $1 bid test, Nasdaq closes matter - Stock Titan ue, 21 Apr 2026 11
- PSTV stock on track for best week since September — here’s what is driving the rally - MSN ue, 21 Apr 2026 00
- Plus Therapeutics (PSTV) CDO receives new options and RSU grants - Stock Titan Wed, 22 Apr 2026 21
- Plus Therapeutics (PSTV) CDO reports no common stock ownership - Stock Titan ue, 21 Apr 2026 21
- Plus Therapeutics (NASDAQ: PSTV) back in line with Nasdaq bid rules - Stock Titan ue, 21 Apr 2026 12
- To keep its Nasdaq listing, Plus Therapeutics enacts 1-for-25 split - Stock Titan ue, 31 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
15.30
+4.10%
|
14.70
+10.31%
|
13.32
-32.42%
|
19.71
|
| Research And Development |
|
8.38
-20.80%
|
10.58
+9.18%
|
9.69
-0.08%
|
9.70
|
| Selling General And Administration |
|
12.13
+22.06%
|
9.94
+16.33%
|
8.54
-16.55%
|
10.24
|
| General And Administrative Expense |
|
12.13
+22.06%
|
9.94
+16.33%
|
8.54
-16.55%
|
10.24
|
| Salaries And Wages |
|
—
|
—
|
—
|
0.52
|
| Other Gand A |
|
12.13
+22.06%
|
9.94
+16.33%
|
8.54
-16.55%
|
10.24
|
| Other Operating Expenses |
|
-5.21
+10.49%
|
-5.82
-18.54%
|
-4.91
-2093.30%
|
-0.22
|
| Total Expenses |
|
15.30
+4.10%
|
14.70
+10.31%
|
13.32
-32.42%
|
19.71
|
| Operating Income |
|
-15.30
-4.10%
|
-14.70
-10.31%
|
-13.32
+32.42%
|
-19.71
|
| Total Operating Income As Reported |
|
-15.30
-4.10%
|
-14.70
-10.31%
|
-13.32
+32.42%
|
-19.71
|
| EBITDA |
|
-18.33
-118.71%
|
-8.38
+31.81%
|
-12.29
+35.11%
|
-18.95
|
| Normalized EBITDA |
|
-15.70
-11.86%
|
-14.04
-14.18%
|
-12.29
+35.11%
|
-18.95
|
| Reconciled Depreciation |
|
0.45
-48.97%
|
0.87
+38.85%
|
0.63
+1.45%
|
0.62
|
| EBIT |
|
-18.78
-102.91%
|
-9.25
+28.38%
|
-12.92
+33.96%
|
-19.56
|
| Total Unusual Items |
|
-2.63
-146.53%
|
5.65
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-2.63
-146.53%
|
5.65
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-22.39
-72.49%
|
-12.98
+2.54%
|
-13.32
+34.32%
|
-20.27
|
| Pretax Income |
|
-22.39
-72.49%
|
-12.98
+2.54%
|
-13.32
+34.32%
|
-20.27
|
| Net Non Operating Interest Income Expense |
|
-3.49
-1.22%
|
-3.45
-69120.00%
|
0.01
+100.89%
|
-0.56
|
| Interest Expense Non Operating |
|
3.61
-3.09%
|
3.72
+842.78%
|
0.40
-44.44%
|
0.71
|
| Net Interest Income |
|
-3.49
-1.22%
|
-3.45
-69120.00%
|
0.01
+100.89%
|
-0.56
|
| Interest Expense |
|
3.61
-3.09%
|
3.72
+842.78%
|
0.40
-44.44%
|
0.71
|
| Interest Income Non Operating |
|
0.12
-57.51%
|
0.27
-31.75%
|
0.40
+172.11%
|
0.15
|
| Interest Income |
|
0.12
-57.51%
|
0.27
-31.75%
|
0.40
+172.11%
|
0.15
|
| Other Income Expense |
|
-3.60
-169.56%
|
5.17
|
—
|
0.00
|
| Other Non Operating Income Expenses |
|
-0.96
-98.35%
|
-0.49
|
—
|
0.00
|
| Gain On Sale Of Security |
|
-2.63
-146.53%
|
5.65
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-22.39
-72.49%
|
-12.98
+2.54%
|
-13.32
+34.32%
|
-20.27
|
| Net Income From Continuing Operation Net Minority Interest |
|
-22.39
-72.49%
|
-12.98
+2.54%
|
-13.32
+34.32%
|
-20.27
|
| Net Income From Continuing And Discontinued Operation |
|
-22.39
-72.49%
|
-12.98
+2.54%
|
-13.32
+34.32%
|
-20.27
|
| Net Income Continuous Operations |
|
-22.39
-72.49%
|
-12.98
+2.54%
|
-13.32
+34.32%
|
-20.27
|
| Normalized Income |
|
-19.75
-6.03%
|
-18.63
-39.92%
|
-13.32
+34.32%
|
-20.27
|
| Net Income Common Stockholders |
|
-22.39
-72.49%
|
-12.98
+2.54%
|
-13.32
+34.32%
|
-20.27
|
| Diluted EPS |
|
-0.29
+99.50%
|
-58.50
+44.81%
|
-106.00
+63.29%
|
-288.75
|
| Basic EPS |
|
-0.29
+99.41%
|
-48.75
+54.01%
|
-106.00
+63.29%
|
-288.75
|
| Basic Average Shares |
|
77.80
+29192.80%
|
0.27
+111.41%
|
0.13
+79.45%
|
0.07
|
| Diluted Average Shares |
|
77.80
+25158.78%
|
0.31
+145.17%
|
0.13
+79.45%
|
0.07
|
| Diluted NI Availto Com Stockholders |
|
-22.39
-24.19%
|
-18.02
-35.36%
|
-13.32
+34.32%
|
-20.27
|
| Average Dilution Earnings |
|
0.00
+100.00%
|
-5.05
|
—
|
—
|
| Gain On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets |
|
16.32
+146.12%
|
6.63
-41.75%
|
11.39
|
| Current Assets |
|
15.17
+188.46%
|
5.26
-46.52%
|
9.83
|
| Cash Cash Equivalents And Short Term Investments |
|
8.61
+138.82%
|
3.61
-57.84%
|
8.55
|
| Cash And Cash Equivalents |
|
4.26
+5500.00%
|
0.08
-99.11%
|
8.55
|
| Other Short Term Investments |
|
4.36
+23.40%
|
3.53
|
0.00
|
| Receivables |
|
0.32
-43.61%
|
0.57
|
0.00
|
| Other Receivables |
|
0.32
-43.61%
|
0.57
|
—
|
| Prepaid Assets |
|
1.34
+107.43%
|
0.65
-38.24%
|
1.05
|
| Current Deferred Assets |
|
0.39
-9.63%
|
0.44
+86.32%
|
0.23
|
| Restricted Cash |
|
4.50
|
0.00
|
—
|
| Other Current Assets |
|
—
|
—
|
—
|
| Total Non Current Assets |
|
1.16
-15.94%
|
1.37
-11.58%
|
1.55
|
| Net PPE |
|
0.33
-37.24%
|
0.52
-52.98%
|
1.11
|
| Gross PPE |
|
3.66
+0.03%
|
3.66
+0.47%
|
3.64
|
| Accumulated Depreciation |
|
-3.33
-6.21%
|
-3.14
-23.82%
|
-2.54
|
| Properties |
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.78
+0.22%
|
1.78
+8.95%
|
1.63
|
| Other Properties |
|
0.07
-4.11%
|
0.07
-63.86%
|
0.20
|
| Leases |
|
1.81
+0.00%
|
1.81
+0.00%
|
1.81
|
| Goodwill And Other Intangible Assets |
|
0.70
-16.17%
|
0.84
+103.14%
|
0.41
|
| Goodwill |
|
0.37
+0.00%
|
0.37
+0.00%
|
0.37
|
| Other Intangible Assets |
|
0.33
-29.00%
|
0.47
+1016.67%
|
0.04
|
| Other Non Current Assets |
|
0.12
+925.00%
|
0.01
-62.50%
|
0.03
|
| Total Liabilities Net Minority Interest |
|
12.33
-20.88%
|
15.58
+22.35%
|
12.74
|
| Current Liabilities |
|
12.31
-20.82%
|
15.55
+44.97%
|
10.73
|
| Payables And Accrued Expenses |
|
5.50
-49.70%
|
10.93
+74.60%
|
6.26
|
| Payables |
|
3.28
-65.42%
|
9.47
+99.12%
|
4.76
|
| Accounts Payable |
|
3.28
-65.42%
|
9.47
+99.12%
|
4.76
|
| Current Accrued Expenses |
|
2.22
+52.47%
|
1.46
-2.99%
|
1.50
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.42
+18.26%
|
0.36
-3.78%
|
0.37
|
| Current Debt And Capital Lease Obligation |
|
0.81
-75.84%
|
3.34
-18.55%
|
4.10
|
| Current Debt |
|
0.75
-77.22%
|
3.29
-17.20%
|
3.98
|
| Other Current Borrowings |
|
—
|
—
|
3.98
|
| Current Capital Lease Obligation |
|
0.06
+27.27%
|
0.04
-63.33%
|
0.12
|
| Current Deferred Liabilities |
|
0.93
+0.00%
|
0.93
|
0.00
|
| Current Deferred Revenue |
|
0.93
+0.00%
|
0.93
|
0.00
|
| Other Current Liabilities |
|
4.66
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.01
-51.61%
|
0.03
-98.46%
|
2.01
|
| Long Term Debt And Capital Lease Obligation |
|
0.01
-51.61%
|
0.03
-63.53%
|
0.09
|
| Long Term Debt |
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
0.01
-51.61%
|
0.03
-63.53%
|
0.09
|
| Non Current Deferred Liabilities |
|
—
|
0.00
-100.00%
|
1.92
|
| Non Current Deferred Revenue |
|
—
|
0.00
-100.00%
|
1.92
|
| Stockholders Equity |
|
4.00
+144.65%
|
-8.95
-563.87%
|
-1.35
|
| Common Stock Equity |
|
4.00
+144.65%
|
-8.95
-563.87%
|
-1.35
|
| Capital Stock |
|
0.14
+2216.67%
|
0.01
+20.00%
|
0.01
|
| Common Stock |
|
0.14
+2216.67%
|
0.01
+20.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
5.56
+2157.35%
|
0.25
+36.09%
|
0.18
|
| Ordinary Shares Number |
|
5.55
+2251.90%
|
0.24
+32.68%
|
0.18
|
| Treasury Shares Number |
|
0.01
+0.00%
|
0.01
+228.99%
|
0.00
|
| Additional Paid In Capital |
|
520.22
+7.26%
|
485.02
+1.20%
|
479.27
|
| Retained Earnings |
|
-515.87
-4.54%
|
-493.48
-2.70%
|
-480.50
|
| Treasury Stock |
|
0.50
+0.00%
|
0.50
+296.83%
|
0.13
|
| Total Equity Gross Minority Interest |
|
4.00
+144.65%
|
-8.95
-563.87%
|
-1.35
|
| Total Capitalization |
|
4.00
+144.65%
|
-8.95
-563.87%
|
-1.35
|
| Working Capital |
|
2.86
+127.75%
|
-10.29
-1052.52%
|
-0.89
|
| Invested Capital |
|
4.75
+183.90%
|
-5.66
-315.26%
|
2.63
|
| Total Debt |
|
0.82
-75.62%
|
3.37
-19.47%
|
4.18
|
| Net Debt |
|
—
|
3.22
|
—
|
| Capital Lease Obligations |
|
0.07
-5.33%
|
0.07
-63.41%
|
0.20
|
| Net Tangible Assets |
|
3.29
+133.62%
|
-9.79
-455.62%
|
-1.76
|
| Tangible Book Value |
|
3.29
+133.62%
|
-9.79
-455.62%
|
-1.76
|
| Derivative Product Liabilities |
|
—
|
—
|
—
|
| Interest Payable |
|
0.00
-100.00%
|
0.12
|
0.00
|
| Line Of Credit |
|
0.75
-77.22%
|
3.29
-17.20%
|
3.98
|
| Preferred Shares Number |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-20.77
-96.84%
|
-10.55
+17.87%
|
-12.85
+0.93%
|
-12.97
|
| Cash Flow From Continuing Operating Activities |
|
-20.77
-96.84%
|
-10.55
+17.87%
|
-12.85
+0.93%
|
-12.97
|
| Net Income From Continuing Operations |
|
-22.39
-72.49%
|
-12.98
+2.54%
|
-13.32
+34.32%
|
-20.27
|
| Depreciation Amortization Depletion |
|
0.45
-48.97%
|
0.87
+38.85%
|
0.63
+1.45%
|
0.62
|
| Depreciation |
|
—
|
0.60
+0.00%
|
0.60
+20.00%
|
0.50
|
| Amortization Cash Flow |
|
—
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Depreciation And Amortization |
|
0.45
-48.97%
|
0.87
+38.85%
|
0.63
+1.45%
|
0.62
|
| Amortization Of Intangibles |
|
—
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Other Non Cash Items |
|
3.06
-13.65%
|
3.54
+828.01%
|
0.38
-1.55%
|
0.39
|
| Stock Based Compensation |
|
1.54
+180.00%
|
0.55
-3.34%
|
0.57
-6.11%
|
0.61
|
| Asset Impairment Charge |
|
—
|
—
|
0.12
+25.81%
|
0.09
|
| Operating Gains Losses |
|
2.62
+146.25%
|
-5.65
-282800.00%
|
0.00
|
—
|
| Gain Loss On Investment Securities |
|
2.63
+146.53%
|
-5.65
|
—
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
—
|
-0.00
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.00
|
0.00
|
| Change In Working Capital |
|
-6.04
-287.49%
|
3.22
+388.71%
|
-1.12
-119.94%
|
5.60
|
| Change In Receivables |
|
0.25
+143.61%
|
-0.57
|
0.00
|
—
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
—
|
| Change In Payables And Accrued Expense |
|
-5.62
-219.52%
|
4.70
+227.88%
|
-3.68
-156.99%
|
6.45
|
| Change In Other Working Capital |
|
—
|
-1.00
-454.80%
|
0.28
-82.90%
|
1.64
|
| Change In Other Current Assets |
|
-0.76
-450.00%
|
0.22
-90.91%
|
2.40
+201.18%
|
-2.37
|
| Change In Other Current Liabilities |
|
0.09
+171.54%
|
-0.13
-11.11%
|
-0.12
+9.30%
|
-0.13
|
| Investing Cash Flow |
|
-0.85
+79.23%
|
-4.11
-2469.38%
|
-0.16
+78.92%
|
-0.76
|
| Cash Flow From Continuing Investing Activities |
|
-0.85
+79.23%
|
-4.11
-2469.38%
|
-0.16
+78.92%
|
-0.76
|
| Net PPE Purchase And Sale |
|
-0.04
+74.66%
|
-0.15
+8.75%
|
-0.16
+68.57%
|
-0.51
|
| Purchase Of PPE |
|
-0.07
+54.11%
|
-0.15
+8.75%
|
-0.16
+68.57%
|
-0.51
|
| Sale Of PPE |
|
0.03
|
0.00
|
—
|
0.00
|
| Capital Expenditure |
|
-0.07
+90.30%
|
-0.69
-331.88%
|
-0.16
+78.92%
|
-0.76
|
| Net Investment Purchase And Sale |
|
-0.82
+76.11%
|
-3.42
|
0.00
|
—
|
| Purchase Of Investment |
|
-9.35
+40.01%
|
-15.59
|
0.00
|
—
|
| Sale Of Investment |
|
8.54
-29.86%
|
12.17
|
0.00
|
—
|
| Net Intangibles Purchase And Sale |
|
0.00
+100.00%
|
-0.55
|
0.00
+100.00%
|
-0.25
|
| Purchase Of Intangibles |
|
0.00
+100.00%
|
-0.55
|
0.00
+100.00%
|
-0.25
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
-0.25
|
| Financing Cash Flow |
|
30.31
+389.91%
|
6.19
+79.59%
|
3.44
-74.39%
|
13.45
|
| Cash Flow From Continuing Financing Activities |
|
30.31
+389.91%
|
6.19
+79.59%
|
3.44
-74.39%
|
13.45
|
| Net Issuance Payments Of Debt |
|
-2.51
-256.11%
|
-0.70
+56.22%
|
-1.61
+0.00%
|
-1.61
|
| Issuance Of Debt |
|
4.49
+36.33%
|
3.29
|
0.00
|
—
|
| Repayment Of Debt |
|
-7.00
-75.05%
|
-4.00
-148.51%
|
-1.61
+0.00%
|
-1.61
|
| Long Term Debt Issuance |
|
3.74
|
0.00
|
—
|
—
|
| Long Term Debt Payments |
|
-3.70
+7.33%
|
-4.00
-148.51%
|
-1.61
+0.00%
|
-1.61
|
| Net Long Term Debt Issuance |
|
0.04
+100.88%
|
-4.00
-148.51%
|
-1.61
+0.00%
|
-1.61
|
| Short Term Debt Issuance |
|
0.75
-77.22%
|
3.29
|
0.00
|
—
|
| Short Term Debt Payments |
|
-3.29
|
0.00
|
—
|
—
|
| Net Short Term Debt Issuance |
|
-2.54
-177.22%
|
3.29
|
0.00
|
—
|
| Net Common Stock Issuance |
|
38.54
+459.29%
|
6.89
+27.59%
|
5.40
-65.89%
|
15.83
|
| Common Stock Payments |
|
0.00
+100.00%
|
-0.37
-196.83%
|
-0.13
|
0.00
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-0.37
-196.83%
|
-0.13
|
0.00
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
—
|
0.00
|
| Net Other Financing Charges |
|
-5.72
|
—
|
-0.35
+54.98%
|
-0.77
|
| Changes In Cash |
|
8.68
+202.41%
|
-8.48
+11.37%
|
-9.57
-3316.43%
|
-0.28
|
| Beginning Cash Position |
|
0.08
-99.11%
|
8.55
-52.79%
|
18.12
-1.52%
|
18.40
|
| End Cash Position |
|
8.76
+11423.68%
|
0.08
-99.11%
|
8.55
-52.79%
|
18.12
|
| Free Cash Flow |
|
-20.84
-85.34%
|
-11.24
+13.57%
|
-13.01
+5.24%
|
-13.73
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.03
-85.59%
|
0.22
-32.11%
|
0.33
|
| Amortization Of Securities |
|
-0.01
+91.89%
|
-0.11
|
0.00
|
—
|
| Common Stock Issuance |
|
38.54
+430.50%
|
7.26
+31.45%
|
5.53
-65.09%
|
15.83
|
| Issuance Of Capital Stock |
|
38.54
+430.50%
|
7.26
+31.45%
|
5.53
-65.09%
|
15.83
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-22 View
- 8-K2026-04-21 View
- 8-K2026-04-09 View
- 8-K2026-04-08 View
- 8-K2026-04-02 View
- 42026-04-01 View
- 42026-04-01 View
- 8-K2026-03-26 View
- 8-K2026-03-12 View
- 10-K2026-03-12 View
- 8-K2026-03-12 View
- 42026-02-27 View
- 42026-02-27 View
- 8-K2026-02-13 View
- 8-K2026-01-22 View
- 8-K2026-01-16 View
- 42026-01-02 View
- 42026-01-02 View
- 8-K2025-11-17 View
- 42025-11-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|